Thursday, 5 November 2026European Markets

BELIEVE Stock Went Up By Over 11% So Far On Monday

Loading stream...

(vianews) - shares of believe (cac 40: blv.pa) rose by a staggering 11.55% to €10.82 at 14:52 est on monday, following the last session's upward trend. cac 40 is jumping 0.1% to €7,491.50, after two sequential sessions in a row of gains. this seems, up to now, a somewhat up trend exchanging session today.

believe's last close was €10.82, 10.58% under its 52-week high of €12.10.

about believe

believe s.a. provides music distribution and marketing services for artists and labels worldwide. the company's physical and digital distribution services include a range of digital music services and video streaming, as well as a network of physical distribution partners. it also provides trade marketing, video, sync, and additional services; and technology and analytics for clients to manage and promote their catalog. believe s.a. was incorporated in 2005 and is headquartered in paris, france.

earnings per share

as for profitability, believe has a trailing twelve months eps of €-0.19.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -6.32%.

moving average

believe's value is above its 50-day moving average of €10.63 and above its 200-day moving average of €10.07.

sales growth

believe's sales growth for the current quarter is 22.5%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, believe's stock is considered to be oversold (<=20).

volume

today's last reported volume for believe is 49782 which is 187.84% above its average volume of 17295.

more news about believe (blv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com